Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Accumulated Expenses (2017 - 2024)

Arcadia Biosciences (RKDA) has disclosed Accumulated Expenses for 11 consecutive years, with $962000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Accumulated Expenses fell 14.03% year-over-year to $962000.0, compared with a TTM value of $962000.0 through Dec 2024, down 14.03%, and an annual FY2024 reading of $962000.0, down 14.03% over the prior year.
  • Accumulated Expenses was $962000.0 for Q4 2024 at Arcadia Biosciences, down from $1.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.1 million in Q4 2023 and bottomed at $6000.0 in Q4 2022.
  • Average Accumulated Expenses over 5 years is $482800.0, with a median of $276000.0 recorded in 2020.
  • The sharpest move saw Accumulated Expenses crashed 88.24% in 2022, then skyrocketed 18550.0% in 2023.
  • Year by year, Accumulated Expenses stood at $276000.0 in 2020, then plummeted by 81.52% to $51000.0 in 2021, then plummeted by 88.24% to $6000.0 in 2022, then surged by 18550.0% to $1.1 million in 2023, then fell by 14.03% to $962000.0 in 2024.
  • Business Quant data shows Accumulated Expenses for RKDA at $962000.0 in Q4 2024, $1.1 million in Q4 2023, and $6000.0 in Q4 2022.